Navigation Links
Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
Date:11/11/2008

CRANBURY, N.J., Nov. 11 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), today announced President and CEO, John F. Crowley, will make a presentation at the 5th Annual Lazard Capital Markets Healthcare Conference in New York on Tuesday, November 18, 2008, at 5:10 p.m. EST.

A webcast and audio archive of the presentation will be available at the Company's Web site at http://www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's Web site for 30 days until December 18, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Amicus' press releases are available at http://www.amicustherapeutics.com

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... Calcivis, a medical devices ... decay, today announces that it has completed a ... Imaging System. The Calcivis Caries Activity ... consumable combination designed to transform the assessment and ... a unique, proprietary bioluminescence approach combined with a ...
(Date:11/26/2014)... The report on the Global Smart ... concerned market for revenue forecasts and market trends. It ... 51.9% from 2013 to 2018. At the projected rate, ... $1,415.6 million by 2018. , Browse through the Global ... information about the market segmentation and in-depth analysis supported ...
(Date:11/26/2014)... IL (PRWEB) November 26, 2014 In ... is giving customers a bevy of last-minute Thanksgiving savings. ... codes and offers across all product lines this holiday ... , Thanksgiving, Black Friday, and Cyber Monday are ... its' own thanks to both loyal customers and those ...
(Date:11/26/2014)... MADRID , Nov. 26, 2014 ... presented results from a survey of European physicians ... Meeting on Innovation and Biological Therapies" at the ... The event, hosted by EuropaBio and the Spanish ... Ministry of Health, physicians from Spanish oncology and ...
Breaking Biology Technology:Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 2Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 4DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3ASBM Presents European Physicians Survey at Spanish Ministry of Health 2
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), ... and commercialization of novel drugs in the,therapeutic ... today,announced that it was added to the ... reconstituted its comprehensive set of U.S. and,global ...
... 3 /Xinhua-PRNewswire-FirstCall/ -- Huifeng,Bio-Pharmaceutical Technology, Inc. (OTC ... of plant extracts and pharmaceutical raw materials,for ... in China,announced today that its company information ... Market Access Program, an information distribution,service that ...
... to offer choice of two distinct drugs on ... separate drug-eluting stent platforms, NATICK, ... today announced that the U.S. Food and Drug,Administration (FDA) has ... coronary artery disease. The,PROMUS Stent is a private-labeled XIENCE(TM) V ...
Cached Biology Technology:Advanced Life Sciences Added to Russell Microcap Index 2Advanced Life Sciences Added to Russell Microcap Index 3Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poor's Market Access Program 2Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 2Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 3Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 4
(Date:11/4/2014)... – University of Utah engineers developed the first room-temperature ... produce electricity without needing to ignite the fuel. These ... electronics, off-grid power and sensors. , A study of ... Chemical Society journal ACS Catalysis . , Fuel ... between a fuel and an oxygen-rich source such as ...
(Date:11/4/2014)... Medicine announced today that it is a Grand ... Bill & Melinda Gates Foundation. Laura Goetzl, ... Sciences; and Vice Chair of Research and Academic ... pursue an innovative global health and development research ... Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals worldwide ...
(Date:11/4/2014)... research study examining only marketing directed at children ... restaurants has found that the majority of black, ... such marketing tactics. , Authored by Arizona State ... study is the first to examine the use ... of fast food restaurants and its relationship to ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... Calif.Even though wildfires have increased in size over time, ... negative impacts to the ecosystem, according to a recently ... . A team of scientists from the USDA ... the size, severity and frequency of wildfires on four ...
... are very important in fundamental research on cellbiomaterial ... been extensively investigated during the last decade. Natural ... conventionally been used to block cell adhesion. Zhao ... that the purple membrane (PM) containing a natural ...
... CORAL GABLES, FL -- Certain kinds of male birds ... perform their courtship dances, and according to science, who they ... of Miami Evolutionary Biologist J. Albert Uy and his collaborators ... if they gather with close male kin, than in the ...
Cached Biology News:Study of wildfire trends in Northwestern California shows no increase in severity over time 2New function of a bacterial photoresponsive protein: Resisting adhesion of mammalian cells 2Why birds of a feather lek together 2
SpectroQuest single beam 1.8nm UV/Vis spectrophotometer; stand-alone unit...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Size & Applications: 20 ml Storage Temp.: -20C Shelf Life: 12 months ...
... Immunogen: Synthetic peptide derived from ... protein (chromosome 17 open reading frame 37 ... for the C35 protein. On Western blots ... kDa band. Reactivity: Human (positive control: ...
Biology Products: